"Drugs giant Shire Pharmaceuticals was given a much needed boost after UBS said Anglo-Swedish peer AstraZeneca could afford to pay up to £14.25 a share in cash for the business and still create value."
http://www.telegraph.co.uk/money/main.jhtml?xml=/money/2008/03/19/cxmktrep119.xml
Wednesday, March 19, 2008
SHP
